Immunome (IMNM) Stock Overview
A biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IMNM Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Immunome, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.41 |
| 52 Week High | US$27.65 |
| 52 Week Low | US$5.15 |
| Beta | 2.2 |
| 1 Month Change | -7.73% |
| 3 Month Change | -5.99% |
| 1 Year Change | 180.36% |
| 3 Year Change | 304.16% |
| 5 Year Change | -36.87% |
| Change since IPO | 51.75% |
Recent News & Updates
Recent updates
Immunome Can Take The Fight To Competitors With Varegacestat
Jan 30Immunome: A Recently Acquired Lead Asset And A Small Market
Dec 11Immunome: Why It Has Doubled Over The Last Month
Jan 18Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?
Mar 17
Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?
Nov 20Immunome GAAP EPS of -$0.74
Aug 05Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation
Aug 05Immunome gains 34% after preclinical data on COVID-19 antibody
Jun 30We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth
Feb 21Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth
Oct 02Shareholder Returns
| IMNM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | 0.4% | -1.6% |
| 1Y | 180.4% | 23.9% | 15.2% |
Return vs Industry: IMNM exceeded the US Biotechs industry which returned 25% over the past year.
Return vs Market: IMNM exceeded the US Market which returned 15.9% over the past year.
Price Volatility
| IMNM volatility | |
|---|---|
| IMNM Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IMNM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMNM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 177 | Clay Siegall | immunome.com |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.
Immunome, Inc. Fundamentals Summary
| IMNM fundamental statistics | |
|---|---|
| Market cap | US$2.30b |
| Earnings (TTM) | -US$212.39m |
| Revenue (TTM) | US$6.94m |
Is IMNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMNM income statement (TTM) | |
|---|---|
| Revenue | US$6.94m |
| Cost of Revenue | US$177.29m |
| Gross Profit | -US$170.34m |
| Other Expenses | US$42.05m |
| Earnings | -US$212.39m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | -2,454.19% |
| Net Profit Margin | -3,059.99% |
| Debt/Equity Ratio | 0% |
How did IMNM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/26 09:05 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunome, Inc. is covered by 14 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam Vogel | Craig-Hallum Capital Group LLC |
| Cory Kasimov | Evercore ISI |
| Salveen Richter | Goldman Sachs |